PIK3CA and breast carcinoma: Most recently, Fulvestrant with Alpelisib, an α-selective PI3K inhibitor, has been recently approved for cases who have progressed on an endocrine therapeutic process with PIK3CA mutated breast carcinoma (Soleja et al., 2019).